Phase 1 N=35 Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.
Inflammation · Cataract
Primary: Visual Acuity — 20.3; 20.2 units on a scale — p=.374
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=10 Subarachnoid Administrations of Adults Autologous Mesenchymal Stromal Cells in SCI
Spinal Cord Injury
Primary: Efficacy-Sensivity Improvement Using the ASIA Score — 188.2; 202.2; 218.4; 228.9 units on a scale
Phase 1 N=49 A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)
Infectious Disease
Primary: Part 1: Area Under the Plasma Concentration-time Curve From Dosing to Infinity (AUC0-inf) of MK-7655 in Combination With PRIMAXIN® — 73.5; 45.0; 115; 52.3 µM*hr
Phase 1 N=24 Safety and Tolerability of the Ophthalmic Gel PRO-167 Versus Corneregel® on Healthy Subjects.
Dry Eye · Dry Eye Syndrome of Unspecified Lacrimal Gland
Primary: Goblet Cell Density (GCD) — 444; 440 cells/mm^2 — p=0.285
Phase 1 N=26 A Study of Two Dosage Forms of LY2886721 in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY2886721 — 183; 195; 181; 173 nanograms / milliliter (ng/mL)
Phase 1 N=30 Safety and Tolerability of PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Healthy Subjects
Dry Eye Syndromes · Lubricant Allergy · Tear Disorder
Primary: Goblet Cell Density (GCD) — 282.5; 326.8; 291.5 cells/mm2 — p=0.273
Phase 1 N=20 Rimeporide in Patients With Duchenne Muscular Dystrophy
Muscular Dystrophy, Duchenne
Primary: Number of Participants With Adverse Events — 2; 1; 5; 4 Participants
Phase 1 N=9 Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients
Healthy Volunteers · Breast Cancer
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0 Participants
Phase 1 N=30 OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients
Chronic Pain
Primary: AUC0-48hr of Noroxycodone Plasma Concentration. — 81.72; 325.51 hr*ng/mL
Phase 1 N=40 Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Metformin — 5033.8718; 6142.2821; 6090.7932 nanogram*hour per…
Phase 1 N=29 Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009)
Neoplasms
Primary: Number of Participants Who Experienced an Adverse Event — 1; 2; 1; 2 Participants
Phase 1 N=12 Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)
HIV-1 Infection
Primary: Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA) at 168 Hours Post-Dose — -1.06; -0.95 log10 (copies/mL)
Phase 1 N=44 Glucophage Immediate Release (GIR) China Bioequivalence Study
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of Metformin (GIR Tablet Active Ingredient) — 6260; 6280; 4950; 5020…
Phase 1 N=12 This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men
Healthy
Primary: Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Verapamil + R1 (T1) vs. R1)…
Phase 1 N=39 Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)
Ebola Viruses
Primary: Percentage of Participants With 1 or More Unsolicited AE : Vaccination 1 — 60.0; 70.0; 50.0; 44.4 Percentage of participants